851702-96-0Relevant articles and documents
Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity Relationship
Vianello, Paola,Sartori, Luca,Amigoni, Federica,Cappa, Anna,Fagá, Giovanni,Fattori, Raimondo,Legnaghi, Elena,Ciossani, Giuseppe,Mattevi, Andrea,Meroni, Giuseppe,Moretti, Loris,Cecatiello, Valentina,Pasqualato, Sebastiano,Romussi, Alessia,Thaler, Florian,Trifiró, Paolo,Villa, Manuela,Botrugno, Oronza A.,Dessanti, Paola,Minucci, Saverio,Vultaggio, Stefania,Zagarrí, Elisa,Varasi, Mario,Mercurio, Ciro
, p. 1693 - 1715 (2017)
The balance of methylation levels at histone H3 lysine 4 (H3K4) is regulated by KDM1A (LSD1). KDM1A is overexpressed in several tumor types, thus representing an emerging target for the development of novel cancer therapeutics. We have previously describe
THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS
-
Page/Page column 54; 55, (2016/05/02)
The present application relates to thienopyrrole derivatives, compounds of Formulae (I) and (la), wherein R, R1, R2 and R3 are as defined in the specification, pharmaceutical compositions containing such compounds and to t
2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS
-
Page/Page column 636, (2008/06/13)
The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: (1)in the above formula (1), R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R1 and -(C